Last updated: September 2, 2026
Acetaminophen/tramadol hydrochloride is a mature, largely commoditized combination analgesic sold under the brand Ultracet and multiple generic labels. The product has limited remaining intellectual-property leverage, no biologic or biosimilar exposure, and declining branded revenue potential. Commercial value is concentrated in low-cost generic volume, hospital and retail distribution, contract manufacturing, and portfolio access rather than product differentiation.
What is the acetaminophen/tramadol hydrochloride product?
Acetaminophen/tramadol hydrochloride combines two analgesics with different mechanisms:
- Acetaminophen provides non-opioid analgesic and antipyretic activity.
- Tramadol hydrochloride is a centrally acting opioid analgesic with additional serotonin and norepinephrine reuptake effects.
- The U.S. branded product is Ultracet, originally marketed by Ortho-McNeil, a Johnson & Johnson company.
- The immediate-release tablet contains 37.5 mg tramadol hydrochloride and 325 mg acetaminophen.
- The FDA-approved indication is short-term management of acute pain severe enough to require an opioid analgesic when alternative treatments are inadequate.[1]
The combination has a commercial advantage over single-agent tramadol for some acute-pain prescriptions because it permits lower tramadol exposure per tablet. Its principal limitations are opioid-related controls, acetaminophen liver-toxicity restrictions, dependence risk, drug-interaction warnings, and competition from inexpensive single-ingredient products.
When was Ultracet approved and when did generic competition begin?
The FDA approved Ultracet in September 2001.[2] The product entered a market in which tramadol was already established and acetaminophen was widely available as an over-the-counter analgesic. The combination therefore had a limited opportunity to command a sustained premium.
Key regulatory timeline
| Event |
Timing |
Commercial significance |
| Tramadol introduced internationally |
1970s |
Established the active pharmaceutical ingredient before the combination product |
| Ultracet FDA approval |
September 2001 |
Created the U.S. branded combination product |
| U.S. opioid scheduling of tramadol |
August 2014 |
Increased prescribing, compliance, and distribution friction |
| FDA approval of lower-acetaminophen Ultracet formulation |
2011 |
Reduced tablet acetaminophen content from 325 mg to 300 mg in the original formulation context |
| Generic combination products |
2000s-2010s |
Eliminated most U.S. branded pricing power |
| Current market |
2020s |
Generic-dominated, with no meaningful originator exclusivity |
FDA approved generic tramadol hydrochloride/acetaminophen tablets from multiple manufacturers, including major generic suppliers such as Actavis, Par Pharmaceutical, and others. Generic availability has kept the product accessible but has compressed average selling prices.
What patents protect acetaminophen and tramadol hydrochloride?
The core composition-of-matter protection for tramadol is no longer commercially relevant in the United States. The original tramadol patent estate dates from the 1970s and expired long ago. Combination-product patents and related formulation rights also expired or lost practical market value before the current generic market matured.
Patent-estate assessment
| Patent category |
Current position |
Competitive effect |
| Tramadol active ingredient |
Expired |
No composition-of-matter barrier |
| Acetaminophen active ingredient |
Long expired |
No proprietary protection |
| Immediate-release combination |
Legacy rights expired or commercially exhausted |
Generic entry permitted |
| Method-of-use patents |
Limited practical value |
Narrow enforcement potential |
| Manufacturing processes |
Potentially relevant at supplier level |
Usually does not block finished-dose competition |
| Formulation patents |
Limited for standard immediate-release tablets |
Weak differentiation |
| Data exclusivity |
Expired |
No regulatory exclusivity barrier |
The most important U.S. patent issue is historical rather than current. Originator protection for tramadol and the combination product has expired, and the FDA-approved immediate-release tablet is available through abbreviated new drug applications.
The Orange Book remains the principal source for current U.S. listed patents and regulatory exclusivity. Because Orange Book listings can change through delisting, expiration, or product-status updates, commercial diligence should rely on the current FDA entry rather than historical patent databases.[3]
What is the Orange Book status of acetaminophen/tramadol hydrochloride?
The combination is an approved small-molecule prescription product with generic equivalents. The branded Ultracet product does not have commercially meaningful remaining U.S. regulatory exclusivity.
The relevant FDA pathway is the ANDA process. Generic applicants must demonstrate pharmaceutical equivalence and bioequivalence to the reference-listed drug. They do not repeat the full clinical efficacy program required for the original NDA.
Paragraph IV challenge exposure
Paragraph IV litigation risk is now limited because the core product rights have expired. Historically, a generic applicant could file a Paragraph IV certification against listed patents, potentially triggering a 30-month stay under the Hatch-Waxman Act. That mechanism was important during the transition from branded Ultracet to generic competition.
For current entrants, the main risks are more likely to involve:
- Product-specific FDA deficiencies.
- Bioequivalence or dissolution failures.
- Manufacturing observations.
- Controlled-substance compliance.
- Supply-chain qualification.
- Commercial price erosion.
A new Paragraph IV campaign against the basic immediate-release combination would have limited economic value unless a later-listed, narrow formulation or method-of-use patent created a defensible market segment.
How strong is the patent estate for acetaminophen/tramadol hydrochloride?
The patent estate is weak for standard generic competition and moderate only for narrow manufacturing, delivery, or formulation claims.
Strength by business objective
| Objective |
Patent strength |
Assessment |
| Block a conventional generic tablet |
Low |
Core rights are expired |
| Preserve branded pricing |
Very low |
Multiple generic suppliers constrain price |
| Protect a modified-release product |
Moderate if claims are technically narrow |
Requires clinical and manufacturing differentiation |
| Protect a fixed-dose combination process |
Low to moderate |
Process patents may be designed around |
| Protect a new abuse-deterrent formulation |
Potentially moderate |
Development and regulatory costs are high |
| Secure hospital formulary share |
Not primarily patent-driven |
Depends on price, supply, and contracting |
| Protect geographic markets outside the U.S. |
Variable |
Rights depend on local filing and expiry history |
Manufacturing patents can still matter commercially. A supplier may own crystallization, impurity-control, granulation, or tablet-compression claims. Those rights generally create a risk-management issue rather than a durable barrier to multiple-source generic supply.
How did opioid regulation change market dynamics?
Tramadol was placed into Schedule IV under the U.S. Controlled Substances Act in August 2014.[4] The scheduling decision altered the commercial profile of the combination.
The main effects were:
- Prescribers faced additional controlled-substance documentation and monitoring requirements.
- Pharmacies and wholesalers incurred greater compliance obligations.
- Manufacturers had to manage quota, security, recordkeeping, and diversion controls.
- Some patients and prescribers shifted toward non-opioid alternatives.
- Tramadol retained broader use than higher-schedule opioids because its perceived abuse potential was lower, but that advantage narrowed after scheduling.
The product occupies an intermediate position. It is more regulated than acetaminophen or nonsteroidal anti-inflammatory drugs, but generally less commercially restricted than Schedule II opioids. Its market is therefore sensitive to state prescribing laws, opioid stewardship programs, payer policies, and institutional formularies.
What is the competitive landscape?
The combination competes against both drug products and therapeutic alternatives.
Direct competitors
- Generic tramadol hydrochloride.
- Generic acetaminophen/tramadol hydrochloride.
- Branded Ultracet, where available.
- Other fixed-dose analgesic combinations.
Indirect competitors
- Acetaminophen alone.
- Ibuprofen and other nonsteroidal anti-inflammatory drugs.
- Short-course hydrocodone/acetaminophen.
- Codeine/acetaminophen.
- Tapentadol.
- Nonpharmacologic pain management.
- Regional anesthetic and postoperative pain protocols.
Generic tramadol is a particularly strong substitute. A prescriber can titrate tramadol separately from acetaminophen, while the fixed-dose combination imposes a predetermined ratio. That reduces the combination's usefulness when a patient requires individualized dose adjustment or must limit acetaminophen exposure.
The combination has greater relevance in acute outpatient pain than in chronic pain management. Opioid stewardship has reduced the attractiveness of long-term use, while emergency departments, dental practices, orthopedic procedures, and short postoperative courses remain important channels.
What formulations are protected or commercially differentiated?
The standard product is an immediate-release tablet. It has limited differentiation because the manufacturing process is familiar and the active ingredients are widely available.
Potentially differentiated approaches include:
- Extended-release tramadol with separate acetaminophen dosing.
- Abuse-deterrent tramadol formulations.
- Lower-acetaminophen tablets.
- Pediatric or geriatric dosage formats.
- Orally disintegrating tablets.
- Combination products with alternative opioid-to-nonopioid ratios.
- Blister packaging and adherence-oriented packaging.
These concepts face a commercial tradeoff. A new formulation could obtain patent protection, but it would also require clinical development, FDA review, controlled-substance compliance, and reimbursement justification. A premium product must demonstrate a measurable safety, adherence, dosing, or convenience benefit over inexpensive generics.
What is the financial trajectory of the product?
The financial trajectory is mature-to-declining for branded sales and stable-to-competitive for generic volume.
Branded economics
Ultracet's branded revenue potential deteriorated after generic entry. The product has no meaningful remaining market exclusivity, and the combination does not have the scale or differentiation of a major chronic-care medicine. Public company reporting generally does not disclose Ultracet revenue as a separate line item, so product-level revenue cannot be reliably extracted from Johnson & Johnson's consolidated filings.[5]
The financial pattern is typical of an older prescription product:
- High initial margin before generic entry.
- Rapid price erosion after ANDA approvals.
- Reduced promotional spending.
- Greater reliance on legacy demand and channel availability.
- Eventual migration to low-volume branded or authorized-generic sales.
Generic economics
Generic manufacturers can generate returns through volume and manufacturing efficiency, but margins are exposed to:
- Additional suppliers entering the market.
- Pharmacy benefit manager purchasing pressure.
- Wholesaler consolidation.
- Active pharmaceutical ingredient costs.
- Controlled-substance compliance costs.
- Product recalls and manufacturing interruptions.
- Low reimbursement ceilings.
- Hospital tendering.
The combination may remain commercially viable because tablets are inexpensive to manufacture and demand is recurring. Its economic value is more attractive to a supplier with an established opioid manufacturing platform than to a new entrant building a standalone business.
Revenue exposure by stakeholder
| Stakeholder |
Exposure |
| Originator |
Low and declining |
| Generic manufacturers |
Moderate volume opportunity, low unit margin |
| API suppliers |
Stable but price-sensitive demand |
| Wholesalers |
Low-margin distribution volume |
| Retail pharmacies |
Dispensing revenue subject to reimbursement pressure |
| Hospitals |
Procurement savings from generic supply |
| Payers |
Lower drug cost, but opioid-related utilization risk |
| Investors |
Limited standalone growth unless linked to a broader generic portfolio |
What generic launch scenarios exist?
Base case: continued commoditization
Multiple suppliers remain active, prices stay low, and market share moves according to availability and contracting. This is the most likely scenario.
Upside case for manufacturers: supplier exit
Quality problems, API shortages, controlled-substance quota limits, or a recall could reduce supplier count. Remaining manufacturers could see temporary volume and price improvement. Such gains would likely be cyclical rather than structural.
Downside case: opioid-use reduction
Tighter prescribing controls, payer restrictions, and substitution by non-opioid therapies could reduce unit demand. The decline would likely be gradual because tramadol remains established in acute-pain practice.
Specialty case: reformulated product
A lower-acetaminophen, abuse-deterrent, or modified-release product could create a premium segment. The product would require meaningful clinical or regulatory differentiation and would face generic substitution once relevant exclusivity ends.
What licensing deals and litigation affect the market?
No major current licensing transaction is central to the commercial value of standard acetaminophen/tramadol hydrochloride in the United States. The originator's historical rights have expired, and generic manufacturers generally rely on ANDA approvals rather than licensing the original brand.
Litigation risk is also limited for the legacy immediate-release product. The more relevant legal matters are:
- Controlled-substance compliance.
- Opioid marketing and distribution litigation.
- Product-liability claims involving respiratory depression, dependence, overdose, or acetaminophen hepatotoxicity.
- ANDA litigation involving later reformulations.
- Manufacturing and quality disputes.
The FDA label warns about seizures, serotonin syndrome, respiratory depression, addiction, misuse, abuse, and acetaminophen-related liver injury.[1] Those risks can affect product liability reserves, insurance costs, pharmacovigilance obligations, and corporate compliance programs even when patent litigation is absent.
What geographic markets remain attractive?
The United States is a low-price, high-compliance market. Generic penetration is high, but volume remains substantial because of the size of the prescription market and established use of tramadol.
Commercial conditions vary by region:
- Europe has broad generic availability and country-specific reimbursement controls.
- Canada has mature generic distribution and controlled-substance regulation.
- Emerging markets may have greater demand for low-cost analgesics but variable enforcement of prescription and quality standards.
- Some countries restrict tramadol more aggressively because of misuse and dependence concerns.
- Combination-product availability depends on local registration, dosage limits, and acetaminophen labeling requirements.
Geographic expansion is therefore more likely to produce incremental volume than durable pricing power.
Key Takeaways
- Acetaminophen/tramadol hydrochloride is a mature generic analgesic market.
- Ultracet was FDA-approved in 2001 and has no meaningful remaining U.S. exclusivity.
- Core patents covering tramadol, acetaminophen, and the conventional combination are expired or commercially exhausted.
- Paragraph IV risk is limited for the standard immediate-release tablet.
- The product has no biosimilar pathway because it is a small-molecule drug.
- Tramadol's Schedule IV status increased compliance costs and reduced prescribing flexibility.
- Generic profitability depends on volume, supply reliability, and manufacturing efficiency.
- Branded revenue is structurally weak, while generic demand is stable but price-sensitive.
- Future differentiation would require a modified-release, abuse-deterrent, lower-acetaminophen, or other clinically meaningful formulation.
- The principal commercial risks are price erosion, opioid-use reduction, supplier exits, recalls, and regulatory compliance.
FAQs
Is acetaminophen/tramadol hydrochloride still under patent?
The standard immediate-release combination is no longer protected by commercially meaningful U.S. patent exclusivity. Narrow later patents could apply to specific formulations or manufacturing methods, but they do not generally block conventional generic tablets.
Is tramadol/acetaminophen a Schedule II opioid?
No. In the United States, tramadol is a Schedule IV controlled substance. The combination remains subject to opioid prescribing, dispensing, recordkeeping, and diversion controls.
Does acetaminophen/tramadol have biosimilar competition?
No. Biosimilars apply to biologic products. Acetaminophen/tramadol is a synthetic small-molecule drug and competes through generic ANDA approvals.
Can a company obtain new patents on tramadol/acetaminophen?
Yes, but new protection would generally need to cover a novel formulation, dosing regimen, delivery system, manufacturing process, or other patentable technical feature. A new patent would not restore exclusivity for the old immediate-release tablet.
What is the main investment risk in the acetaminophen/tramadol market?
The main risk is commodity price erosion. Demand may remain, but low reimbursement, generic competition, controlled-substance compliance, and substitution by non-opioid analgesics limit the opportunity for sustained margin expansion.
References
- U.S. Food and Drug Administration. (2023). Ultracet (tramadol hydrochloride and acetaminophen) prescribing information. FDA.
- U.S. Food and Drug Administration. (2001). Drugs@FDA: Ultracet application history. FDA.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
- Drug Enforcement Administration. (2014). Schedules of controlled substances: Placement of tramadol into Schedule IV. 79 Fed. Reg. 37623.
- Johnson & Johnson. (2001-2023). Annual reports and Form 10-K filings. Johnson & Johnson.
